Clinically Meaningful Responses to Fremanezumab in Patients with Migraine and Documented Inadequate Response to 2-4 Classes of Migraine Preventive Medications in the Randomized, Placebo-Controlled FOCUS Study

被引：0

作者：

Spierings, Egilius L. H. ^{[1
]}

Ning, Xiaoping ^{[2
]}

Galic, Maja ^{[3
]}

Cohen, Joshua M. ^{[2
]}

Yang, Ronghua ^{[2
]}

机构：

[1] Medvadis Res Corp, Watertown, MA USA

[2] Teva Pharmaceut Ind, Frazer, PA USA

[3] Teva Pharmaceut, Amsterdam, Netherlands

来源：

ANNALS OF NEUROLOGY | 2019年 / 86卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

M195

引用

页码：S168 / S168

页数：1

共 50 条

[1] Clinically Meaningful Responses to Fremanezumab in Patients with Migraine and Documented Inadequate Response to 2-4 Classes of Migraine Preventive Medications in the Multicenter, Randomized, Placebo-controlled FOCUS Study
Spierings, E.
Ning, X.
Galic, M.
Cohen, J. M.
Yang, R.
HEADACHE, 2019, 59 : 23 - 24
[2] Clinically Meaningful Responses to Fremanezumab in Migraine Patients with Medication Overuse and Documented Inadequate Response to 2-4 Migraine Preventive Medications in the Randomized, Placebo-controlled FOCUS Study
Ashina, Sait
Ramirez-Campos, Verena
Cohen, Joshua
Janka, Lindsay
Spierings, Egilius L. H.
NEUROLOGY, 2020, 94 (15)
[3] Clinically meaningful responses to fremanezumab in patients with migraine and documented inadequate response to 2-4 classes of migraine preventive medications in the international, multicentre, randomised, placebo-controlled FOCUS study
Spierings, Egilius L.
Ning, Xiaoping
Galic, Maja
Cohen, Joshua M.
Yang, Ronghua
CEPHALALGIA, 2019, 39 : 223 - 224
[4] Efficacy and clinically meaningful responses to fremanezumab in patients with migraine and documented inadequate response to 2-4 classes of migraine preventive medications in the international, multicentre, randomised, placebo-controlled FOCUS study
Spierings, E. L.
Ning, X.
Galic, M.
Cohen, J. M.
Yang, R.
EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 809 - 809
[5] Clinically meaningful responses to fremanezumab in migraine patients with medication overuse and documented inadequate response to 2-4 migraine preventive medications in the randomised, placebo-controlled FOCUS study
Ashina, Sait
Ramirez-Campos, Verena
Cohen, Joshua M.
Janka, Lindsay
Spierings, Egilius L.
CEPHALALGIA, 2019, 39 : 227 - 227
[6] Safety and Tolerability of Fremanezumab in Patients with Migraine and Documented Inadequate Response to 2-4 Classes of Migraine Preventive Medications in the Randomized, Placebo-Controlled FOCUS Study
Ferrari, Michel D.
Cohen, Joshua M.
Ning, Xiaoping
Galic, Maja
Yang, Ronghua
ANNALS OF NEUROLOGY, 2019, 86 : S77 - S77
[7] Efficacy and Safety of Fremanezumab in Patients with Migraine and Documented Inadequate Response to 2-4 Classes of Migraine Preventive Medications: Results of the Multicenter, Randomized, Placebo-controlled FOCUS Study
Ferrari, M. D.
Diener, H.
Ning, X.
Galic, M.
Cohen, J. M.
Yang, R.
Ashina, M.
HEADACHE, 2019, 59 : 93 - 94
[8] Safety and Tolerability Outcomes of the Multicenter, Randomized, Placebo-controlled FOCUS Study of Fremanezumab in Patients with Migraine and Documented Inadequate Response to 2-4 Classes of Migraine Preventive Medications
Ferrari, M. D.
Cohen, J. M.
Ning, X.
Galic, M.
Yang, R.
HEADACHE, 2019, 59 : 116 - 117
[9] Efficacy of Fremanezumab in Male Patients With Migraine and Documented Inadequate Response to 2-4 Classes of Migraine Preventive Medication Classes: Results of the Randomized, Placebo-controlled FOCUS Study
MaassenVanDenBrink, Antoinette
Terwindt, Gisela
Cohen, Joshua
Yang, Ronghua
Ramirez-Campos, Verena
Galic, Maja
Ning, Xiaoping
Karppa, Mikko
NEUROLOGY, 2020, 94 (15)
[10] Safety and tolerability of fremanezumab in patients with migraine and documented inadequate response to 2-4 classes of migraine preventive medications in the international, multicentre, randomised, placebo-controlled FOCUS study
Ferrari, M. D.
Cohen, J. M.
Ning, X.
Galic, M.
Yang, R.
EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 625 - 625

← 1 2 3 4 5 →